Botulinum toxin type A reduces histamine‐induced itch and vasomotor responses in human skin

Background  Clinical evidence has revealed the antipruritic effect of botulinum toxin type A (BoNT/A). BoNT/A is believed to be effective against itch as it inhibits the release of acetylcholine as well as some other substances that may be involved in itch.

[1]  L. Arendt-Nielsen,et al.  Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin , 2009, PAIN®.

[2]  M. Donini,et al.  Botulinum toxin type‐A for the treatment of inverse psoriasis , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Greaves.  Recent advances in pathophysiology and current management of itch. , 2007, Annals of the Academy of Medicine, Singapore.

[4]  R. Paus,et al.  TRP channels as novel players in the pathogenesis and therapy of itch. , 2007, Biochimica et biophysica acta.

[5]  P. Weinfeld.  Successful treatment of notalgia paresthetica with botulinum toxin type A. , 2007, Archives of dermatology.

[6]  V. Tugnoli,et al.  Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin , 2007, PAIN.

[7]  Misook Kim,et al.  TRPV1 Mediates Histamine-Induced Itching via the Activation of Phospholipase A2 and 12-Lipoxygenase , 2007, The Journal of Neuroscience.

[8]  Erle C H Lim,et al.  Botulinum toxin, Quo Vadis? , 2007, Medical hypotheses.

[9]  M. Simon,et al.  Phospholipase Cβ 3 Mediates the Scratching Response Activated by the Histamine H1 Receptor on C-Fiber Nociceptive Neurons , 2006, Neuron.

[10]  M. Steinhoff,et al.  Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. , 2006, The Journal of investigative dermatology.

[11]  S. Ständer,et al.  Chronic itch and pain—Similarities and differences , 2006, European journal of pain.

[12]  M. Steinhoff,et al.  The neurobiology of itch , 2006, Nature Reviews Neuroscience.

[13]  R. Paus,et al.  Frontiers in pruritus research: scratching the brain for more effective itch therapy. , 2006, The Journal of clinical investigation.

[14]  S. Feldman,et al.  Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. , 2006, Journal of the American Academy of Dermatology.

[15]  H. Kilbinger,et al.  In vivo release of non‐neuronal acetylcholine from the human skin as measured by dermal microdialysis: effect of botulinum toxin , 2006, British journal of pharmacology.

[16]  J. Ring,et al.  Correlations between histamine-induced wheal, flare and itch , 1996, Archives of Dermatological Research.

[17]  U. Wollina,et al.  Botulinum toxin in dermatology – beyond wrinkles and sweat , 2005, Journal of cosmetic dermatology.

[18]  K. Aoki.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. , 2005, Neurotoxicology.

[19]  D. Cockayne,et al.  Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. , 2005, The Journal of urology.

[20]  J. Carruthers,et al.  Botulinum toxin type A. , 2005, Journal of the American Academy of Dermatology.

[21]  J. Wallengren.  Neuroanatomy and neurophysiology of itch , 2005, Dermatologic therapy.

[22]  M. Schmelz,et al.  Electrically evoked itch in humans , 2005, Pain.

[23]  M. Greaves,et al.  Itch: More than Skin Deep , 2004, International Archives of Allergy and Immunology.

[24]  E. Mayer,et al.  Protease-Activated Receptor 2 Sensitizes the Capsaicin Receptor Transient Receptor Potential Vanilloid Receptor 1 to Induce Hyperalgesia , 2004, The Journal of Neuroscience.

[25]  K. Aoki,et al.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain , 2004, Pain.

[26]  A. Klein.  Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. , 2004, Journal of the American Academy of Dermatology.

[27]  T. Luger,et al.  Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. , 2008, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  T. Luger,et al.  Neurophysiology of pruritus: cutaneous elicitation of itch. , 2003, Archives of dermatology.

[29]  O. Doğu,et al.  Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial , 2003, Acta oto-laryngologica.

[30]  H O Handwerker,et al.  Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. , 2003, Journal of neurophysiology.

[31]  H. Kilbinger,et al.  Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. , 2003, Life sciences.

[32]  F. Birklein,et al.  Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin , 2003, Journal of Neurology.

[33]  A. Fleischer,et al.  Itch associated with skin disease: advances in pathophysiology and emerging therapies. , 2003, American Journal of Clinical Dermatology.

[34]  J. Arezzo.  Possible Mechanisms for the Effects of Botulinum Toxin on Pain , 2002, The Clinical journal of pain.

[35]  I. Gibbins,et al.  Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. , 2002, American journal of physiology. Heart and circulatory physiology.

[36]  P. Flecknell,et al.  Production of acute and chronic itch with histamine and contact sensitizers in the mouse and guinea pig , 2002, Experimental dermatology.

[37]  G. Plewig,et al.  Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. , 2002, Journal of the American Academy of Dermatology.

[38]  M. Schmelz,et al.  Itch--mediators and mechanisms. , 2002, Journal of dermatological science.

[39]  U. Wollina,et al.  Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left–right comparison , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[40]  C. R. Daniel,et al.  Cost of atopic dermatitis and eczema in the United States. , 2001, Journal of the American Academy of Dermatology.

[41]  E. Stålberg,et al.  Side‐effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study , 2001, European journal of neurology.

[42]  F. Erbguth,et al.  Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry , 2001, The British journal of dermatology.

[43]  K. Shimizu,et al.  [Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles]. , 2000, Nippon Ganka Gakkai zasshi.

[44]  A. Craig,et al.  Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch , 2001, Nature Neuroscience.

[45]  M. Schmelz.  A neural pathway for itch , 2001, Nature Neuroscience.

[46]  M. Hallett.  How does botulinum toxin work? , 2000, Annals of neurology.

[47]  K. Foster,et al.  Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. , 2000, Biochemical pharmacology.

[48]  H. E. Torebjörk,et al.  Which nerve fibers mediate the axon reflex flare in human skin? , 2000, Neuroreport.

[49]  C. Wahlgren.  Itch and Atopic Dermatitis: An Overview , 1999, The Journal of dermatology.

[50]  Hermann O. Handwerker,et al.  Specific C-Receptors for Itch in Human Skin , 1997, The Journal of Neuroscience.

[51]  O. Hornstein,et al.  Acetylcholine Is an Inducer of Itching in Patients with Atopic Eczema , 1997, The Journal of dermatology.

[52]  C. Wahlgren,et al.  Measurement of itch. , 1995, Seminars in dermatology.

[53]  R. Spiewak.  Inter- and intra-individual variability of skin reactivity to histamine at prick-testing. , 1995 .

[54]  C. Liisberg,et al.  Precise area determination of skin‐prick tests: validation of a scanning device and software for a personal computer , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[55]  R. Gonnering,et al.  Pharmacology of Botulinum Toxin , 1993, International ophthalmology clinics.

[56]  M. Verhage,et al.  Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action. , 1992, The Journal of biological chemistry.

[57]  D. Tobin,et al.  Increased number of immunoreactive nerve fibers in atopic dermatitis. , 1992, The Journal of allergy and clinical immunology.

[58]  Smith Tf.  Allergy testing in clinical practice. , 1992 .

[59]  T. F. Smith.  Allergy testing in clinical practice. , 1992, Annals of allergy.

[60]  C. Wahlgren.  Itch and atopic dermatitis: clinical and experimental studies. , 1991, Acta dermato-venereologica. Supplementum.

[61]  O. Hornstein,et al.  Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. , 1991, Acta dermato-venereologica.

[62]  R. LaMotte,et al.  Psychophysical studies of the itch sensation and itchy skin ("alloknesis") produced by intracutaneous injection of histamine. , 1991, Somatosensory & motor research.

[63]  H O Handwerker,et al.  Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. , 1990, The Journal of investigative dermatology.

[64]  H O Handwerker,et al.  Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. , 1989, The Journal of investigative dermatology.

[65]  K. Aktories,et al.  Inhibition of histamine release from rat mast cells by botulinum C2 toxin. , 1987, International archives of allergy and applied immunology.

[66]  R. LaMotte,et al.  The magnitude and duration of itch produced by intracutaneous injections of histamine. , 1987, Somatosensory research.

[67]  Bartlett Ms.  The use of transformations. , 1947 .

[68]  M. Bartlett,et al.  The use of transformations. , 1947, Biometrics.